Treatment for Nonalcoholic Steatohepatitis Linked Cirrhosis Will Continue Into Phase 3 Trials
According to a story from globenewswire.com, the drug development company Galectin Therapeutics, Inc., recently announced its plans to go forward with Phase 3 trials for GR-MD-02. The company is dedicated…